Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antipsychotics: classification, efficacy, and adverse effects.

J Gerlach1

  • 1St. Hans Hospital, Roskilde, Denmark.

Schizophrenia Bulletin
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

THE MIDLATITUDE CONTINENTAL CONVECTIVE CLOUDS EXPERIMENT (MC3E).

Bulletin of the American Meteorological Society·2020
Same author

Improved method for MR microscopy of brain tissue cultured with the interface method combined with Lenz lenses.

Magnetic resonance imaging·2018
Same author

Hypersensitivity pneumonitis and antigen identification--An alternate approach.

Respiratory medicine·2016
Same author

Principles of practice from the European expert panel on the contemporary treatment of schizophrenia.

International journal of psychiatry in clinical practice·2014
Same author

Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Extracellular serine proteases from Stenotrophomonas maltophilia: Screening, isolation and heterologous expression in E. coli.

Journal of biotechnology·2011
Same journal

Reconsidering the Term "Treatment Resistant Schizophrenia".

Schizophrenia bulletin·2026
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
See all related articles

New antipsychotics offer lower extrapyramidal side effects (EPS) than traditional drugs. Research reviews dopamine D2/D3 blockers, D1 antagonists, partial D2 agonists, and non-dopamine agents for schizophrenia treatment.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Traditional neuroleptics often cause significant extrapyramidal side effects (EPS).
  • Newer antipsychotic agents are being developed to improve efficacy and reduce side effects.
  • Understanding receptor interactions is key to developing better treatments for psychosis.

Purpose of the Study:

  • To review the efficacy and side effect profiles of various classes of new and potential antipsychotic drugs.
  • To compare the effects of dopamine receptor antagonists and agonists on EPS and antipsychotic activity.
  • To explore the therapeutic potential of non-dopaminergic agents in schizophrenia treatment.

Main Methods:

  • Review of existing literature on antipsychotic drug classes.

Related Experiment Videos

  • Analysis of receptor binding profiles and their correlation with clinical effects.
  • Comparison of efficacy and side effect data for different drug categories.

    • Main Results:

    • Dopamine (DA) D2/D3 receptor blockers show low EPS and comparable efficacy to traditional neuroleptics.
    • D1 antagonists exhibit low EPS in primates, suggesting potential as novel antipsychotics.
    • Non-dopamine agents like serotonin (5HT) and GABA-A agonists may offer adjunctive benefits or novel antipsychotic effects.
    • Antipsychotics targeting multiple receptors (D2/D3, 5HT, alpha 1, D1) demonstrate the most potent antipsychotic effects.

    Conclusions:

    • Newer antipsychotics, particularly those with multi-receptor activity, offer improved side effect profiles and potent efficacy.
    • Targeting specific dopamine receptor subtypes or exploring non-dopaminergic pathways presents promising avenues for schizophrenia treatment.
    • Further research into agents like 5HT3 antagonists and partial glutamate agonists may yield effective antipsychotic therapies.